Skip to main content
HR 5850 118th Congress House Health Abortion Drug safety, medical device, and laboratory regulation Prescription drugs

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act…

Show full title

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Introduced: September 29, 2023 Introduced by: Mann, Tracey Republican · Kansas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 6, 2023
Referred to the Subcommittee on Health.
Sep 29, 2023
Referred to the House Committee on Energy and Commerce.
Sep 29, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now October 6, 2023

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1
R
Moolenaar, John R.
Michigan · Sep 29, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5850: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.. 118th Congress. Open America. https://openamerica.io/bill/118-HR-5850/
MLA
"H.R. 5850: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-5850/.
Bluebook (legal)
H.R. 5850, 118th Cong. (2026), https://openamerica.io/bill/118-HR-5850/.
Markdown link
[H.R. 5850: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.](https://openamerica.io/bill/118-HR-5850/)
Report a problem